People

Inside a startup’s pivot to have AI fight coronavirus

Insilico Medicine repurposed its machine learning systems to dream up treatments for coronavirus. Its CEO says it's going well — but the process isn't without hiccups.

Alex Zhavoronkov, the co-founder and CEO of Insilico Medicine

Insilico Medicine's Alex Zhavoronkov is hoping that AI can help speed development of a drug for COVID-19.

Photo: Courtesy of Insilico

With almost half a million reported cases of coronavirus around the world now, the race is on to develop a treatment. Alex Zhavoronkov, the co-founder and CEO of Insilico Medicine, is among those who think that artificial intelligence could help expedite a market-ready drug.

His Hong Kong-based biotech company has repurposed its platforms for the fight against COVID-19. It aims to use "a huge Lego system" of machine learning techniques for drug discovery — and, in this case, Insilico's algorithms have dreamed up tens of thousands of unique molecules that could potentially handicap the protein responsible for the virus' spread.


Get what matters in tech, in your inbox every morning. Sign up for Source Code.


The company's approach isn't without risk. In order to increase the potential drug's selectivity and decrease side effects, Insilico is banking on non-covalent-binding molecules. Unlike other treatments, these will only bind to what they're designed for: one type of COVID-19 protein. That means there's less of a chance of these molecules being successful — but if they do meet their goal, it'll ultimately be more accurate than another approach.

It also isn't without hype: The company has claimed that it can dramatically accelerate the drug development process using machine learning — and that it hopes to begin testing on humans within a couple of months.

Protocol spoke with Zhavoronkov about how Insilico repurposed its platform for virus research, the setbacks the company experienced after the onset of COVID-19, and why he believes machine learning could shorten the timeline for getting coronavirus drugs into clinical trials.

This interview has been edited for length and clarity.

Tell us about the before and after for your company when it comes to the novel coronavirus. What kinds of projects and technologies were you prioritizing before?

Wow, that's a very unusual question because it's an insider's view. We spent more than $10 million on a generative chemistry platform that essentially combines many machine learning techniques together — generative adversarial networks, reinforcement learning, genetic algorithms. It's essentially a huge Lego system of machine learning algorithms that can handle multiple cases.

We were focusing primarily on cancer, fibrosis and many other diseases, and we still are — so we haven't significantly pivoted in terms of our pipeline. However, we've prioritized several projects related to COVID-19 specifically. One of the three parts of our pipeline is focused on mining massive amounts of omics data to be able to find potential therapeutic targets. We've repurposed that for viruses right now.

When news of COVID-19 hit, what was the scramble like?

In early January, we learned about COVID-19. In mid-January, we recognized that there was a problem. In late January, I brought it to my board members and investors and said, "Hey guys, let's work on this." Some of them were not very happy about it because they thought it would go away, just like SARS. (If you remember what happened with SARS, everybody who started drug discovery programs lost because the funding disappeared, and it was really not prioritized as it should have been.) We ended up deciding to use our generative chemistry pipeline — which is ready and specifically designed for these kinds of cases — on some of the most validated, best targets for COVID-19. On Jan. 28, we started the program.

How would you describe that pipeline that you repurposed for this coronavirus?

You know how people make deepfakes — those kinds of imaginative videos, which are sometimes used for all kinds of malicious purposes? There's one type where you can create photographs with specific features and properties. We do the same thing but on molecules — we create molecules with specific properties. In layman's terms, it's essentially imaginative AI. You're creating billions of examples, some virtual, and making deep neural networks imagine new molecular structures that fit into a specific protein target.

Tell us more about how you're using reinforcement learning in this context. I hear you're employing it to encourage the molecules to go after specific objectives?

One approach is when you have a crystal structure of the protein target, so you know the shape and how [the protein] looks. Once we have that, we use AI to "sniff" the shape for binding pockets where a molecule can fit. (When you fit the protein with a small molecule, it disables it.) Once it identifies those pockets, it imagines new molecules — hundreds of thousands of molecules — that could fit onto it. Those molecules do not exist in nature. They are imagined.

And afterward, we have a set of reinforcement learning algorithms that essentially make this AI imagination more robust. You imagine with a specific objective in mind; you want to have very high activity, and you want to have selectivity, and you want to have safety. We generated a bunch of compounds: 100,000 unique molecules, then narrowed it down to 100 and chose seven from there.

How did the onset and spread of COVID-19 affect your lab processes, even as you were researching the virus?

We got into a little bit of trouble because, at that time, the epidemic was very active in Asia. And the way the drug discovery industry is organized … specifically for chemical synthesis, most people do it externally.

It's kind of like Apple, right? They don't assemble their own machines. They send it to Foxconn or some other contract manufacturer, which assembles it for Apple based on its instructions. That's what we're doing at Insilico: We don't have our own lab, but we work with more than 80 other labs worldwide, from which we order experiments.

About 90% of our chemistry is synthesized in China by contract research organizations. And it turned out that when we published our structures, it was still the middle of the Chinese New Year — and right afterward, the government extended the new year. Nobody was working. Nobody could synthesize it for us.

So we decided to publish the molecules. Previously, our generative chemistry approach was sometimes criticized for not making diverse enough molecules. This time, many medicinal chemists looked at the molecules, and they liked them.

How will you continue the process?

We've synthesized one molecule so far. Later on, we'll send it for the ultimate test: to see if it works in virus-infected cells. And after that, we need to do an animal test. Only after that can we test on humans. Technically this process, even though we've accelerated it, might take nine months to get the molecule into humans — maybe sooner, depending on how quickly we can ramp it up.

We've [also] identified a couple of other really promising targets, so we're going to publish more molecules.

You've said you hope to have something ready for clinical trials as soon as April. It usually takes more than a year to ready a prospective drug for human testing. How has AI whittled it down to months?

They'll probably be ready for human testing in a couple of months. But in about two weeks, we'll have the results from the assays, or experimental systems — we'll know whether those molecules worked. If you go the standard route, after you've proven the efficacy in vitro and in mice, then you have to apply for the phase one clinical study — and even the application takes a long time. It's more of a bureaucracy than anything else. And bureaucracy is there for a very good reason, so we aren't going to break any rules.

But when our system spits out the molecules, they are usually very druglike — they require either minimal modifications or none at all. The chances are very high that we can make the claim that they are ready because they have all the properties of a good drug. That's the beauty of AI versus everything else: We don't need to have many cycles of synthesis.


Get in touch with us: Share information securely with Protocol via encrypted Signal or WhatsApp message, at 415-214-4715 or through our anonymous SecureDrop.


So the reason the process usually takes about a year is that you typically need many cycles of synthesis, but since you're using these new techniques, you believe they'll likely be ready in just a few months?

That's absolutely correct. Also, here we took a little bit of a riskier approach. There are two ways of designing those molecules. We know other companies are working on what's called covalent inhibitors; they're inhibitors that bind to the main protease strongly as well as many other things, so they're less selective and there might be side effects. But we designed noncovalent binders. So far, there are no known noncovalent binders for the main protease.

In our case, it's really kind of like when you bet $1 million on a boxer. You're waiting for a match. My next two weeks are that: I'm waiting on those molecules to see which one works and which one performs better.

Climate

A pro-China disinformation campaign is targeting rare earth miners

It’s uncommon for cyber criminals to target private industry. But a new operation has cast doubt on miners looking to gain a foothold in the West in an apparent attempt to protect China’s upper hand in a market that has become increasingly vital.

It is very uncommon for coordinated disinformation operations to target private industry, rather than governments or civil society, a cybersecurity expert says.

Photo: Goh Seng Chong/Bloomberg via Getty Images

Just when we thought the renewable energy supply chains couldn’t get more fraught, a sophisticated disinformation campaign has taken to social media to further complicate things.

Known as Dragonbridge, the campaign has existed for at least three years, but in the last few months it has shifted its focus to target several mining companies “with negative messaging in response to potential or planned rare earths production activities.” It was initially uncovered by cybersecurity firm Mandiant and peddles narratives in the Chinese interest via its network of thousands of fake social media accounts.

Keep Reading Show less
Lisa Martine Jenkins

Lisa Martine Jenkins is a senior reporter at Protocol covering climate. Lisa previously wrote for Morning Consult, Chemical Watch and the Associated Press. Lisa is currently based in Brooklyn, and is originally from the Bay Area. Find her on Twitter ( @l_m_j_) or reach out via email (ljenkins@protocol.com).

Some of the most astounding tech-enabled advances of the next decade, from cutting-edge medical research to urban traffic control and factory floor optimization, will be enabled by a device often smaller than a thumbnail: the memory chip.

While vast amounts of data are created, stored and processed every moment — by some estimates, 2.5 quintillion bytes daily — the insights in that code are unlocked by the memory chips that hold it and transfer it. “Memory will propel the next 10 years into the most transformative years in human history,” said Sanjay Mehrotra, president and CEO of Micron Technology.

Keep Reading Show less
James Daly
James Daly has a deep knowledge of creating brand voice identity, including understanding various audiences and targeting messaging accordingly. He enjoys commissioning, editing, writing, and business development, particularly in launching new ventures and building passionate audiences. Daly has led teams large and small to multiple awards and quantifiable success through a strategy built on teamwork, passion, fact-checking, intelligence, analytics, and audience growth while meeting budget goals and production deadlines in fast-paced environments. Daly is the Editorial Director of 2030 Media and a contributor at Wired.
Fintech

Ripple’s CEO threatens to leave the US if it loses SEC case

CEO Brad Garlinghouse said a few countries have reached out to Ripple about relocating.

"There's no doubt that if the SEC doesn't win their case against us that that is good for crypto in the United States,” Brad Garlinghouse told Protocol.

Photo: Stephen McCarthy/Sportsfile for Collision via Getty Images

Ripple CEO Brad Garlinghouse said the crypto company will move to another country if it loses in its legal battle with the SEC.

Garlinghouse said he’s confident that Ripple will prevail against the federal regulator, which accused the company of failing to register roughly $1.4 billion in XRP tokens as securities.

Keep Reading Show less
Benjamin Pimentel

Benjamin Pimentel ( @benpimentel) covers crypto and fintech from San Francisco. He has reported on many of the biggest tech stories over the past 20 years for the San Francisco Chronicle, Dow Jones MarketWatch and Business Insider, from the dot-com crash, the rise of cloud computing, social networking and AI to the impact of the Great Recession and the COVID crisis on Silicon Valley and beyond. He can be reached at bpimentel@protocol.com or via Google Voice at (925) 307-9342.

Policy

The Supreme Court’s EPA ruling is bad news for tech regulation, too

The justices just gave themselves a lot of discretion to smack down agency rules.

The ruling could also endanger work on competition issues by the FTC and net neutrality by the FCC.

Photo: Geoff Livingston/Getty Images

The Supreme Court’s decision last week gutting the Environmental Protection Agency’s ability to regulate greenhouse gas emissions didn’t just signal the conservative justices’ dislike of the Clean Air Act at a moment of climate crisis. It also served as a warning for anyone that would like to see more regulation of Big Tech.

At the heart of Chief Justice John Roberts’ decision in West Virginia v. EPA was a codification of the “major questions doctrine,” which, he wrote, requires “clear congressional authorization” when agencies want to regulate on areas of great “economic and political significance.”

Keep Reading Show less
Ben Brody

Ben Brody (@ BenBrodyDC) is a senior reporter at Protocol focusing on how Congress, courts and agencies affect the online world we live in. He formerly covered tech policy and lobbying (including antitrust, Section 230 and privacy) at Bloomberg News, where he previously reported on the influence industry, government ethics and the 2016 presidential election. Before that, Ben covered business news at CNNMoney and AdAge, and all manner of stories in and around New York. He still loves appearing on the New York news radio he grew up with.

Enterprise

Microsoft and Google are still using emotion AI, but with limits

Microsoft said accessibility goals overrode problems with emotion recognition and Google offers off-the-shelf emotion recognition technology amid growing concern over the controversial AI.

Emotion recognition is a well-established field of computer vision research; however, AI-based technologies used in an attempt to assess people’s emotional states have moved beyond the research phase.

Photo: Microsoft

Microsoft said last month it would no longer provide general use of an AI-based cloud software feature used to infer people’s emotions. However, despite its own admission that emotion recognition technology creates “risks,” it turns out the company will retain its emotion recognition capability in an app used by people with vision loss.

In fact, amid growing concerns over development and use of controversial emotion recognition in everyday software, both Microsoft and Google continue to incorporate the AI-based features in their products.

“The Seeing AI person channel enables you to recognize people and to get a description of them, including an estimate of their age and also their emotion,” said Saqib Shaikh, a software engineering manager and project lead for Seeing AI at Microsoft who helped build the app, in a tutorial about the product in a 2017 Microsoft video.

Keep Reading Show less
Kate Kaye

Kate Kaye is an award-winning multimedia reporter digging deep and telling print, digital and audio stories. She covers AI and data for Protocol. Her reporting on AI and tech ethics issues has been published in OneZero, Fast Company, MIT Technology Review, CityLab, Ad Age and Digiday and heard on NPR. Kate is the creator of RedTailMedia.org and is the author of "Campaign '08: A Turning Point for Digital Media," a book about how the 2008 presidential campaigns used digital media and data.

Latest Stories
Bulletins